Ameliorative effect of Weiling decoction on metabolic associated fatty liver disease based on the gut-liver axis

CUI Beilei; SONG Yijia; GUAN Yajie; ZHANG Qizhen; WU Wenjing; XU Junjiao; LIU Minghao

doi:10.6039/j.issn.1001-0408.2026.19.04

您当前的位置：

首页 >

文章列表页 >

Ameliorative effect of Weiling decoction on metabolic associated fatty liver disease based on the gut-liver axis

更新时间：2026-10-12

- Ameliorative effect of Weiling decoction on metabolic associated fatty liver disease based on the gut-liver axis
- ZHONGGUO YAOFANG Vol. 37, Issue 19, Pages: 2501-2508(2026)
- 作者机构：
  
  1.河南中医药大学第一附属医院脾胃肝胆科，郑州　450003
  2.河南中医药大学第一临床医学院，郑州　450046
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.19.04
  CLC： R965;R285
- Received：06 June 2026，
  
  Revised：2026-09-24，
  
  Accepted：24 September 2026，
  
  Published：15 October 2026
- 稿件说明：
移动端阅览
崔蓓蕾,宋艺佳,管雅捷,等.基于“肠-肝轴”探讨胃苓汤对代谢相关脂肪性肝病的改善作用 [J].中国药房,2026,37(19):2501-2508.

CUI Beilei,SONG Yijia,GUAN Yajie,et al.Ameliorative effect of Weiling decoction on metabolic associated fatty liver disease based on the gut-liver axis[J].ZHONGGUO YAOFANG,2026,37(19):2501-2508.
崔蓓蕾,宋艺佳,管雅捷,等.基于“肠-肝轴”探讨胃苓汤对代谢相关脂肪性肝病的改善作用 [J].中国药房,2026,37(19):2501-2508. DOI： 10.6039/j.issn.1001-0408.2026.19.04.

CUI Beilei,SONG Yijia,GUAN Yajie,et al.Ameliorative effect of Weiling decoction on metabolic associated fatty liver disease based on the gut-liver axis[J].ZHONGGUO YAOFANG,2026,37(19):2501-2508. DOI： 10.6039/j.issn.1001-0408.2026.19.04.

摘要

目的

基于“肠-肝轴”理论，探讨胃苓汤对代谢相关脂肪性肝病（MAFLD）的改善作用。

方法

将雄性C57BL/6J小鼠分为空白组（9只）和造模组（47只），其中造模组小鼠以高脂饲料喂养12周以构建MAFLD模型。将45只造模小鼠随机分为模型组、阳性对照组[二甲双胍，0.2 g/（kg·d）]和胃苓汤低、中、高剂量组[6.17、12.34、24.68 g/（kg·d），以生药量计]，每组9只。各组小鼠每天灌胃相应药液或生理盐水1次，连续4周。末次给药后，比较各组小鼠体重、肝脏质量及肝脏指数，检测其肝功能（丙氨酸转氨酶、天冬氨酸转氨酶）、血脂（总胆固醇、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇）、炎症[肿瘤坏死因子α、白细胞介素6（IL-6）、IL-1β]、氧化应激（丙二醛、超氧化物歧化酶、谷胱甘肽过氧化物酶）及肠道屏障[脂多糖（LPS）、二胺氧化酶、D-乳酸]相关指标水平，观察其肝组织病理改变，检测其空肠组织中紧密连接蛋白[闭锁小带1（ZO-1）、闭合蛋白（occludin）]和肝组织中脂质代谢[固醇调节元件结合蛋白1（SREBP-1）、脂肪酸合酶（FASN）、过氧化物酶体增殖物激活受体α（PPARα）]、炎症通路[Toll样受体4（TLR4）、髓系分化初级反应蛋白88（MyD88）、核因子κB p65（NF-κB p65）]相关蛋白的表达情况，并分析其肠道菌群变化情况。

结果

与模型组相比，胃苓汤各剂量组小鼠肝组织脂肪变性和炎症损伤均明显减轻，体重（实验第16周）、肝脏质量、肝脏指数和肝功能、血脂、炎症、氧化应激、肠道屏障相关指标均普遍改善（

＜0.05）；肝组织中SREBP-1、FASN、TLR4、MyD88蛋白的表达和NF-κB p65蛋白的磷酸化水平均普遍降低或下调（

＜0.05），空肠组织中ZO-1、occludin蛋白和肝组织中PPARα蛋白的表达均普遍升高或上调（

＜0.05）。与模型组相比，胃苓汤高剂量组小鼠肠道菌群的Observed species、Chao1、Ace指数均显著回升（

＜0.05），且其疣微菌门、阿克曼菌属等菌群的相对丰度均显著升高，放线菌门和另枝菌属、粪杆菌属等菌群的相对丰度均显著降低（

＜0.05）。

结论

胃苓汤可改善MAFLD，其作用可能与调节肠道菌群、修复肠道机械屏障、减少LPS易位，进而抑制TLR4/MyD88/NF-κB炎症通路、减轻氧化应激，并调节SREBP-1/FASN与PPARα介导的脂质代谢有关。

Abstract

OBJECTIVE

To investigate the ameliorative effect of Weiling decoction on metabolic associated fatty liver disease （MAFLD） based on the gut-liver axis theory.

METHODS

Male C57BL/6J mice were divided into a blank group （

＝9） and a modeling group （

＝47）. The modeling group was fed a high-fat diet for 12 weeks to establ

ish the MAFLD model. Forty-five modeled mice were randomly divided into a model group， a positive control group [metformin， 0.2 g/（kg·d）

]

， and Weiling decoction low-， medium-， and high-dose groups [6.17， 12.34， 24.68 g/（kg·d）， calculated as crude drug

]

， with 9 mice in each group. Mice in each group received intragastric administration of the corresponding drug solution or normal saline once daily for 4 consecutive weeks. After the last administration， the body weight， liver weight， and liver index were compared among groups； the levels of liver function indicators （alanine transaminase， aspartate transaminase）， lipid indicators （total cholesterol， triglycerides， low-density lipoprotein cholesterol， high-density lipoprotein cholesterol）， inflammatory indicators [tumor necrosis factor-α， interleukin-6 （IL-6）， IL-1β

]

， oxidative stress indicators （malondialdehyde， superoxide dismutase， glutathione peroxidase）， and intestinal barrier indicators [lipopolysaccharide （LPS）， diamine oxidase， D-lactic acid

]

were measured； hepatic pathological changes were observed； the expressions of tight junction proteins [zonula occludens-1 （ZO-1）， occludin

]

in jejunal tissue and proteins related to lipid metabolism [sterol regulatory element-binding protein-1 （SREBP-1）， fatty acid synthase （FASN）， peroxisome proliferator-activated receptor α （PPARα）

]

and inflammatory pathways [Toll-like receptor 4 （TLR4）， myeloid differentiation primary response protein 88 （MyD88）， nuclear factor-κB p65 （NF-κB p65）

]

in liver tissue were detected； and changes in gut microbiota were analyzed.

RESULTS

Compared with the model group， hepatic steatosis and inflammatory injury were significantly alleviated in all Weiling decoction dose groups； body weight （at week 16）， liver weight， liver index， and the levels of liver function indicators， lipid indicators， inflammation indicators， oxidative stress indicators， and intestinal barrier indicators were all generally improved （

＜0.05）. The expressions of SREBP-1， FAS

N， TLR4， and MyD88 and the phosphorylation level of NF-κB p65 in liver tissue were generally decreased or downregulated （

＜0.05）， while the expressions of ZO-1 and occludin in jejunal tissue and PPARα in liver tissue were generally increased or upregulated （

＜0.05）. Compared with the model group， the Observed species， Chao1， and Ace indices of gut microbiota in the Weiling decoction high-dose group were significantly increased （

＜0.05）， and the relative abundances of Verrucomicrobiota，

Akkermansia

， etc. were significantly increased， while those of Actinomycetota，

Alistipes

，

Faecalibaculum

， etc. were significantly decreased （

＜0.05）.

CONCLUSIONS

Weiling decoction can ameliorate MAFLD， and its effect may be associated with regulating gut microbiota， repairing the intestinal mechanical barrier， reducing LPS translocation， thereby inhibiting the TLR4/MyD88/NF-κB inflammatory pathway， alleviating oxidative stress， and regulating SREBP-1/FASN and PPARα-mediated lipid metabolism.

关键词

Keywords

references

Hou M M ， Gu Q ， Cui J W ， et al . Proportion and clinical characteristics of metabolic-associated fatty liver disease and associated liver fibrosis in an urban Chinese population [J ] . Chin Med J ， 2025 ， 138 （ 7 ）： 829 - 837 .

Li Y X ， Yang P P ， Ye J L ， et al . Updated mechanisms of MASLD pathogenesis [J ] . Lipids Health Dis ， 2024 ， 23 （ 1 ）： 117 .

Arvanitakis K ， Koufakis T ， Cholongitas E ， et al . Insights into the results of resmetirom trials； can a thyroid hormone receptor agonist be the holy grail of MASH therapy? [J ] . Pharmacol Ther ， 2025 ， 268 ： 108811 .

杨国亮，李爱丽 . 胃苓汤联合多烯磷脂酰胆碱治疗对NAFLD患者LSM和胰岛素水平的影响 [J ] . 中国处方药， 2024 ， 22 （ 1 ）： 158 - 161 .

张燕燕，严波，郭虎生，等 . 基于MLCK/MLC2信号通路探讨胃苓汤对腹泻型肠易激综合征大鼠肠道屏障功能的影响 [J ] . 河北医学， 2025 ， 31 （ 4 ）： 577 - 582 .

刘奇，郭宏丽 . 新加胃苓汤联合肠道微生态调节剂治疗小儿迁延性腹泻的疗效及对患儿肠道微生态的影响 [J ] . 海南医学， 2020 （ 4 ）： 459 - 462 .

李爱丽，李凤霞，柴仲秋，等 . 基于网络药理学探讨胃苓汤治疗非酒精性脂肪肝的分子机制研究 [J ] . 职业与健康， 2025 ， 41 （ 5 ）： 611 - 616 .

Pan X E ， Chen X Y ， Ma Y ， et al . Chemotaxis-guided nanoplatform for non-alcoholic steatohepatitis therapy via macrophage reprogramming，hepatoprotection and gut microbiome modulation [J ] . Biomaterials ， 2026 ， 326 ： 123694 .

Yang L ， Bi L P ， Jin L L ， et al . Geniposide ameliorates liver fibrosis through reducing oxidative stress and inflammatory response，inhibiting apoptosis and modulating overall metabolism [J ] . Front Pharmacol ， 2021 ， 12 ： 772635 .

Sanchis-Artero L ， Martínez-Blanch J F ， Manresa-Vera S ， et al . Evaluation of changes in intestinal microbiota in Crohn’s disease patients after anti-TNF alpha treatment [J ] . Sci Rep ， 2021 ， 11 （ 1 ）： 10016 .

Sun Y D ， Zhang H ， Gong X L ， et al . Multiomics reveals metformin’s dual role in gut microbiome remodeling and hepatic metabolic reprogramming for MAFLD intervention [J ] . Sci Rep ， 2025 ， 15 ： 22699 .

Zou J J ， Song Q B ， Shaw P C ， et al . Tangerine peel-derived exosome-like nanovesicles alleviate hepatic steatosis induced by type 2 diabetes； evidenced by regulating lipid metabolism and intestinal microflora [J ] . Int J Nanomedicine ， 2024 ， 19 ： 10023 - 10043 .

Sharma S ， Le Guillou D ， Chen J Y . Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis [J ] . Nat Rev Gastroenterol Hepatol ， 2023 ， 20 （ 10 ）： 662 - 678 .

He P K ， Luo Z H ， Liu X J ， et al . Multi-omics reveals rutin directly targets RUNX1 to disrupt the RUNX1/TET2 complex and alleviate NAFLD via TLR4/NF-κB inhibition [J ] . Eur J Pharmacol ， 2026 ， 1023 ： 178862 .

Mohideen K ， Chandrasekar K ， Ramsridhar S ， et al . Assessment of oxidative stress by the estimation of lipid peroxidation marker malondialdehyde （MDA） in patients with chronic periodontitis； a systematic review and meta-analysis [J ] . Int J Dent ， 2023 ， 2023 ： 6014706 .

Li S ， Hu R ， Xu L Y ， et al . Protective effects of salidroside on NAFLD rodent models by alleviating oxidative stress and inflammation； a meta-analysis and mechanism exploration [J ] . Front Pharmacol ， 2026 ， 17 ： 1709953 .

Ren G H ， Bai C C ， Yi S T ， et al . Mechanisms and therapeutic strategies for MAFLD targeting TLR4 signaling pathways [J ] . J Innate Immun ， 2024 ， 16 （ 1 ）： 45 - 55 .

Białek D ， Wunsch E ， Kempińska-Podhorodecka A ， et al . microRNA and protein biomarkers of intestinal permeability in the assessment of metabolic dysfunction-associated steatotic liver disease （MASLD） [J ] . Int J Mol Sci ， 2025 ， 26 （ 23 ）： 11351 .

Obert E ， Strauss R ， Brandon C ， et al . Targeting the tight junction protein，zonula occludens-1，with the connexin43 mimetic peptide，αCT1，reduces VEGF-dependent RPE pathophysiology [J ] . J Mol Med ， 2017 ， 95 （ 5 ）： 535 - 552 .

Ioannou A ， Berkhout M D ， Geerlings S Y ， et al . Akkermansia muciniphila ； biology，microbial ecology，host interactions and therapeutic potential [J ] . Nat Rev Microbiol ， 2025 ， 23 （ 3 ）： 162 - 177 .

Shashni B ， Tajika Y ， Ikeda Y ， et al . Self-assembling polymer-based short chain fatty acid prodrugs ameliorate non-alcoholic steatohepatitis and liver fibrosis [J ] . Biomaterials ， 2023 ， 295 ： 122047 .

Testerman T ， Li Z Y ， Galuppo B ， et al . Insights from shotgun metagenomics into bacterial species and metabolic pathways associated with NAFLD in obese youth [J ] . Hepatol Commun ， 2022 ， 6 （ 8 ）： 1962 - 1974 .

Chen Y ， Xie C ， Lei Y N ， et al . Theabrownin from Qingzhuan tea prevents high-fat diet-induced MASLD via regulating intestinal microbiota [J ] . Biomed Pharmacother ， 2024 ， 174 ： 116582 .

Li X ， Zeng F ， Huang Y F ， et al . The positive effects of Grifola frondosa heteropolysaccharide on NAFLD and regulation of the gut microbiota [J ] . IJMS ， 2019 ， 20 （ 21 ）： 5302 .

Luo X M ， Zhang B Y ， Pan Y H ， et al . Phyllanthus emblica aqueous extract retards hepatic steatosis and fibrosis in NAFLD mice in association with the reshaping of intestinal microecology [J ] . Front Pharmacol ， 2022 ， 13 ： 893561 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of Yiqi yangyin huazhuo tongluo formula in ameliorating diabetic kidney disease by regulating the gut microbiota-LPS/Caspase-11/GSDMD pathway

Mechanism of Qushi huoxue decoction in improving metabolic-associated fatty liver disease through the AMPK/mTOR/ULK1 autophagy signaling pathway

Regulatory effects of tofacitinib combined with methotrexate on gut microbiota and clinical efficacy in patients with rheumatoid arthritis

Effects and mechanisms of action of Yiqi wenyang huwei decoction in improving bronchial asthma in rats

Mechanism of Huangqin decoction in improving ulcerative colitis based on the gut microbiota-tryptophan metabolism-aryl hydrocarbon receptor axis

Related Author

BIAN Hua

ZHANG Lujia

HUANG Shiyu

WANG Yiyuan

GUO Kelei

LI Yingli

HOU Zijun

WEI Yehuang

Related Institution

Henan Provincial Key Laboratory of Zhang Zhongjing Formulae and Immunoregulation， Nanyang Institute of Technology

Zhang Zhongjing School of Chinese Medicine， Nanyang Institute of Technology

School of Nursing， Henan University of Chinese Medicine

Dept. of Hepatology， The Second Affiliated Hospital of Guangxi University of Chinese Medicine

Graduate School， Guangxi University of Chinese Medicine

⁰